Skip to content

Natera, Inc. NTRA Oncology — Revenue recognized

Similar metrics at other companies

BillionToOne, Inc.
 logo
BLLNOncology — Revenue
$10.72M+392%
Guardant Health logo
GHOncology — Total Revenue
$204.95M+36.1%
Eli Lilly logo
LLYOncology — Revenue
$2.27B+16.4%
Lantheus Holdings logo
LNTHOncology — Revenue
$240.92M-6.5%
Medpace Holdings, Inc. logo
MEDPOncology — Total Revenue
$237.56M+60.5%
Jazz Pharmaceuticals logo
JAZZOncology — Revenue from Contract with Customer, Excluding Assessed Tax
$333.4M+45.3%

Other financials

Income statement

See full
Revenue$696.6M+38.8%
Operating income-$93.5M-18.1%
Net income-$85.1M-27.1%
EPS (diluted)-$0.60-20.0%

Balance sheet

See full
Cash & equivalents$1.1B+11.7%
Total debt$240.1M+22.7%
Total equity$1.8B+43.1%
Total assets$2.6B+50.9%

Cash flow

See full
Operating cash flow$40.2M-9.6%
CapEx$22.1M+1.5%
Free cash flow$18.0M-20.3%

Valuation

See full
Market cap$40.37B+86.3%
Enterprise value$39.52B+89.4%
P/S16.1×+5.1×

Profitability

See full
Gross margin42.9%
Operating margin-13%+0.6pp
Net margin-14.6%+0.6pp
FCF margin4.2%-0.5pp

Returns & leverage

See full
Return on equity-29%+4.1pp
Debt / equity0.1×0.0×
Current ratio-0.9×

Where this comes from

Reported directly by Natera, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityRevenueRecognized.

The official record: Natera, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Natera, Inc.'s oncology — revenue recognized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Natera, Inc.'s oncology — revenue recognized?
Natera, Inc. (NTRA) reported oncology — revenue recognized of $100K in Q1 2026.
What does oncology — revenue recognized mean?
This metric measures the total revenue recognized during the reporting period specifically attributable to oncology assay interpretation services. It reflects the value of services delivered to customers, such as clinical laboratories or healthcare providers, in accordance with the company's revenue recognition policies. This is a primary indicator of the commercial adoption and market penetration of the company's oncology diagnostic portfolio.